10月17日，Viking Therapeutics盘中下跌8.01%，报25.1786美元/股，成交额1.24亿美元。
近期可见的消息面上，瑞银于10月15日启动覆盖该股，给予买入评级及94美元目标价；市场统计显示，该股分析师一致评级为买入，平均目标价为95.47美元。
更早之前，公司于10月14日启动口服VK2735治疗肥胖成人的三期项目，包含肥胖且不伴2型糖尿病、以及肥胖合并2型糖尿病两项研究，主要终点均为68周后体重较基线的百分比变化。尽管近期评级与临床推进偏积极，但当日股价仍出现回落。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.